Published in Sci Rep on November 16, 2016
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med (2009) 65.36
Comprehensive molecular characterization of human colon and rectal cancer. Nature (2012) 34.13
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol (2008) 20.89
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest (2011) 14.22
CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer. N Engl J Med (2016) 8.53
A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet (2006) 7.16
A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med (2013) 6.09
The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse. Cell Stem Cell (2011) 4.79
The consensus molecular subtypes of colorectal cancer. Nat Med (2015) 4.35
Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. Nat Med (2013) 4.22
Colorectal cancer and genetic alterations in the Wnt pathway. Oncogene (2006) 4.14
Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol (2010) 3.30
Metastasis-Associated Gene Expression Changes Predict Poor Outcomes in Patients with Dukes Stage B and C Colorectal Cancer. Clin Cancer Res (2009) 3.08
Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. PLoS Med (2013) 2.96
Colorectal cancer: a tale of two sides or a continuum? Gut (2012) 2.85
Identification of a poor-prognosis BRAF-mutant-like population of patients with colon cancer. J Clin Oncol (2012) 2.66
Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. Genes Chromosomes Cancer (2011) 2.14
Jetset: selecting the optimal microarray probe set to represent a gene. BMC Bioinformatics (2011) 2.09
Development and independent validation of a prognostic assay for stage II colon cancer using formalin-fixed paraffin-embedded tissue. J Clin Oncol (2011) 1.84
Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer. J Pathol (2013) 1.71
Association of inflammation-related and microRNA gene expression with cancer-specific mortality of colon adenocarcinoma. Clin Cancer Res (2009) 1.67
ColoGuideEx: a robust gene classifier specific for stage II colorectal cancer prognosis. Gut (2012) 1.63
Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition. Int J Cancer (2013) 1.60
TAZ expression as a prognostic indicator in colorectal cancer. PLoS One (2013) 1.55
Hypoxia-driven gene expression is an independent prognostic factor in stage II and III colon cancer patients. Clin Cancer Res (2014) 1.55
RecurrenceOnline: an online analysis tool to determine breast cancer recurrence and hormone receptor status using microarray data. Breast Cancer Res Treat (2011) 1.43
Translating tumor biology into personalized treatment planning: analytical performance characteristics of the Oncotype DX Colon Cancer Assay. BMC Cancer (2010) 1.38
Prognostic gene expression signature associated with two molecularly distinct subtypes of colorectal cancer. Gut (2011) 1.32
Targeted therapy in metastatic colorectal cancer -- an example of personalised medicine in action. Cancer Treat Rev (2013) 1.24
Chromosomal instability (CIN) phenotype, CIN high or CIN low, predicts survival for colorectal cancer. J Clin Oncol (2012) 1.17
Development of a clinically feasible molecular assay to predict recurrence of stage II colon cancer. J Mol Diagn (2008) 1.17
Multigene prognostic tests in breast cancer: past, present, future. Breast Cancer Res (2015) 1.16
ColoGuidePro: a prognostic 7-gene expression signature for stage III colorectal cancer patients. Clin Cancer Res (2012) 1.11
High intratumoral expression of fibroblast activation protein (FAP) in colon cancer is associated with poorer patient prognosis. Tumour Biol (2013) 1.04
A nineteen gene-based risk score classifier predicts prognosis of colorectal cancer patients. Mol Oncol (2014) 0.97
Gene expression profiling-derived immunohistochemistry signature with high prognostic value in colorectal carcinoma. Gut (2013) 0.94
Comparison of prognostic genomic predictors in colorectal cancer. PLoS One (2013) 0.90
Epithelial-to-mesenchymal transition and oncogenic Ras expression in resistance to the protein kinase Cbeta inhibitor enzastaurin in colon cancer cells. Mol Cancer Ther (2010) 0.90
Clinical Outcome From Oxaliplatin Treatment in Stage II/III Colon Cancer According to Intrinsic Subtypes: Secondary Analysis of NSABP C-07/NRG Oncology Randomized Clinical Trial. JAMA Oncol (2016) 0.88
Generation and external validation of a tumor-derived 5-gene prognostic signature for recurrence of lymph node-negative, invasive colorectal carcinoma. Cancer (2012) 0.85
Effects of RAL signal transduction in KRAS- and BRAF-mutated cells and prognostic potential of the RAL signature in colorectal cancer. Oncotarget (2015) 0.83
REG4 independently predicts better prognosis in non-mucinous colorectal cancer. PLoS One (2014) 0.82
Dynamic classification using case-specific training cohorts outperforms static gene expression signatures in breast cancer. Int J Cancer (2014) 0.80
Association between the expression levels of TAZ, AXL and CTGF and clinicopathological parameters in patients with colon cancer. Oncol Lett (2015) 0.78
VAV3 oncogene expression in colorectal cancer: clinical aspects and functional characterization. Sci Rep (2015) 0.78